Karyopharm Therapeut (KPTI)

$8.38 -0.17 (-1.99%)
Market Cap 144.00M
Revenue (ttm) 146.07M
Net Income (ttm) -196.04M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -134.21%
Debt to Equity Ratio -0.40
Volume 702,500
Avg Vol 599,346
Day's Range N/A - N/A
Shares Out 18.34M
Stochastic %K 24%
Beta 0.13
Analysts Strong Sell
Price Target $15.33

Company Profile

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compounds include XPOVIO in combination with bortezomib and dexamethasone for th...

Industry: Biotechnology
Sector: Healthcare
Phone: 617 658 0600
Address:
85 Wells Avenue, 2nd Floor, Suite 210, Newton, United States
somalight
somalight Mar. 17 at 5:51 PM
$KPTI Is the outcome of this Phase 3 trial really that important? It doesn’t seem like many people are paying attention to whether it succeeds or fails, and I feel like the stock price reaction might be minimal.
1 · Reply
Selfmademan
Selfmademan Mar. 17 at 4:46 PM
$KPTI director, medical writing no longer taking applicants via linkedin... 🤔 hopefully hired and not just deleted. Yeah hopefully stellar results, perhaps tomorrow. Have 1k shares just in case.
0 · Reply
celebratelife
celebratelife Mar. 17 at 1:39 PM
$KPTI I looked at yesterday's options again at the end of the day, and there were a lot of bullish put and call trades. But it's always tell with certainty which side it's on and if it's a open or close. So everything I post here about options, take it as tentative and impression.
0 · Reply
laaarsas
laaarsas Mar. 17 at 1:08 PM
$KPTI I think results tomorrow! Wednesday is good resultsday. Or maybe if data is bad they release Friday?
0 · Reply
hbkstockislife
hbkstockislife Mar. 17 at 12:13 PM
$KPTI results won’t come or what
0 · Reply
celebratelife
celebratelife Mar. 16 at 5:04 PM
$KPTI Just now another big buy of March $17.50 calls at ask (Bullish) - counting price to go above 17.85 in next 4 days. Total: 134100 shares worth traded today and total open calls: 1054300 open interest. $47,000 bet the stock will go over 17.85 this week !!
1 · Reply
celebratelife
celebratelife Mar. 16 at 4:56 PM
$KPTI Solid May 2.50 put sale at bid (Bullish) 50100 shares worth.
0 · Reply
celebratelife
celebratelife Mar. 16 at 4:53 PM
$KPTI solid buy at ask: March $17.50 - 4 days to expiration - somebody thinks data will be released this week. 82700 shares worth.
0 · Reply
celebratelife
celebratelife Mar. 16 at 2:16 PM
$KPTI So far today: Multiple bullish option moves. A March bullish spread sale of put buy of call - based on analysis incl. impl. volt. -- and a bullish call and another bullish put sale April.
0 · Reply
laaarsas
laaarsas Mar. 16 at 12:15 PM
$KPTI data when?
1 · Reply
Latest News on KPTI
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mar 2, 2026, 4:05 PM EST - 15 days ago

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Karyopharm Therapeutics Inc. (KPTI) Q4 2025 Earnings Call Transcript

Feb 12, 2026, 6:14 PM EST - 4 weeks ago

Karyopharm Therapeutics Inc. (KPTI) Q4 2025 Earnings Call Transcript

Karyopharm Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Company Progress

Feb 12, 2026, 7:30 AM EST - 4 weeks ago

Karyopharm Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Company Progress

Karyopharm to Report Fourth Quarter and Full Year 2025 Financial Results on February 12, 2026

Feb 5, 2026, 7:30 AM EST - 5 weeks ago

Karyopharm to Report Fourth Quarter and Full Year 2025 Financial Results on February 12, 2026

Karyopharm Announces Preliminary Unaudited 2025 Revenue and Reiterates Expectation of Delivering Potentially Transformative Phase 3 Data in 2026

Jan 12, 2026, 7:00 AM EST - 2 months ago

Karyopharm Announces Preliminary Unaudited 2025 Revenue and Reiterates Expectation of Delivering Potentially Transformative Phase 3 Data in 2026

Karyopharm to Participate in Baird's Biotech Discovery Series

Dec 8, 2025, 7:00 AM EST - 3 months ago

Karyopharm to Participate in Baird's Biotech Discovery Series

Karyopharm to Participate at the Piper Sandler 37th Annual Healthcare Conference

Dec 1, 2025, 7:00 AM EST - 3 months ago

Karyopharm to Participate at the Piper Sandler 37th Annual Healthcare Conference

Karyopharm Therapeutics Inc. (KPTI) Q3 2025 Earnings Call Transcript

Nov 3, 2025, 1:26 PM EST - 4 months ago

Karyopharm Therapeutics Inc. (KPTI) Q3 2025 Earnings Call Transcript

Karyopharm Reports Third Quarter 2025 Financial Results and Highlights Recent Company Progress

Nov 3, 2025, 7:00 AM EST - 4 months ago

Karyopharm Reports Third Quarter 2025 Financial Results and Highlights Recent Company Progress

Karyopharm to Report Third Quarter 2025 Financial Results on November 3, 2025

Oct 27, 2025, 7:00 AM EDT - 5 months ago

Karyopharm to Report Third Quarter 2025 Financial Results on November 3, 2025

Karyopharm Strengthens Balance Sheet With $100 Million Financing To Extend Cash Runway Into 2026

Oct 8, 2025, 1:31 PM EDT - 5 months ago

Karyopharm Strengthens Balance Sheet With $100 Million Financing To Extend Cash Runway Into 2026

Karyopharm Announces Strategic Financing Transactions to Support Growth; Extends Cash Runway Into Second Quarter of 2026, Beyond Expected Top-Line Readout of Phase 3 SENTRY Trial in Myelofibrosis

Oct 8, 2025, 7:00 AM EDT - 5 months ago

Karyopharm Announces Strategic Financing Transactions to Support Growth; Extends Cash Runway Into Second Quarter of 2026, Beyond Expected Top-Line Readout of Phase 3 SENTRY Trial in Myelofibrosis

Karyopharm Announces Completion of Enrollment in the Phase 3 SENTRY Trial in Myelofibrosis

Sep 10, 2025, 7:00 AM EDT - 6 months ago

Karyopharm Announces Completion of Enrollment in the Phase 3 SENTRY Trial in Myelofibrosis

Karyopharm Therapeutics Inc. (KPTI) Q2 2025 Earnings Call Transcript

Aug 11, 2025, 11:02 AM EDT - 7 months ago

Karyopharm Therapeutics Inc. (KPTI) Q2 2025 Earnings Call Transcript

Karyopharm Reports Second Quarter 2025 Financial Results and Highlights Recent Company Progress

Aug 11, 2025, 7:30 AM EDT - 7 months ago

Karyopharm Reports Second Quarter 2025 Financial Results and Highlights Recent Company Progress

Karyopharm to Report Second Quarter 2025 Financial Results on August 11, 2025

Aug 5, 2025, 7:00 AM EDT - 8 months ago

Karyopharm to Report Second Quarter 2025 Financial Results on August 11, 2025

Karyopharm to Present at the Jefferies Global Healthcare Conference

Jun 3, 2025, 8:00 AM EDT - 10 months ago

Karyopharm to Present at the Jefferies Global Healthcare Conference

Karyopharm to Participate at the 2025 RBC Capital Markets Global Healthcare Conference

May 19, 2025, 7:00 AM EDT - 10 months ago

Karyopharm to Participate at the 2025 RBC Capital Markets Global Healthcare Conference

Karyopharm Announces Poster Presentation on Selinexor in Myelofibrosis at the 2025 European Hematology Association Annual Meeting

May 14, 2025, 9:31 AM EDT - 10 months ago

Karyopharm Announces Poster Presentation on Selinexor in Myelofibrosis at the 2025 European Hematology Association Annual Meeting

These Analysts Revise Their Forecasts On Karyopharm Therapeutics After Q1 Results

May 13, 2025, 1:39 PM EDT - 11 months ago

These Analysts Revise Their Forecasts On Karyopharm Therapeutics After Q1 Results

Karyopharm Therapeutics Inc. (KPTI) Q1 2025 Earnings Call Transcript

May 13, 2025, 7:15 AM EDT - 11 months ago

Karyopharm Therapeutics Inc. (KPTI) Q1 2025 Earnings Call Transcript

Karyopharm Reports First Quarter 2025 Financial Results and Announces New Data in Myelofibrosis that Further Suggests Selinexor May Lead to Meaningful Spleen Volume Reduction, Symptom Improvement, Hemoglobin Stabilization and Disease Modification

May 12, 2025, 4:05 PM EDT - 11 months ago

Karyopharm Reports First Quarter 2025 Financial Results and Announces New Data in Myelofibrosis that Further Suggests Selinexor May Lead to Meaningful Spleen Volume Reduction, Symptom Improvement, Hemoglobin Stabilization and Disease Modification

Karyopharm to Report First Quarter 2025 Financial Results on May 12, 2025

May 8, 2025, 4:05 PM EDT - 11 months ago

Karyopharm to Report First Quarter 2025 Financial Results on May 12, 2025

XPOVIO® (selinexor) Approved for Commercialization in Indonesia, Further Expanding Antengene's Commercial Presence in APAC

Mar 5, 2025, 12:00 AM EST - 1 year ago

XPOVIO® (selinexor) Approved for Commercialization in Indonesia, Further Expanding Antengene's Commercial Presence in APAC

Karyopharm Announces 1-for-15 Reverse Stock Split

Feb 24, 2025, 8:40 AM EST - 1 year ago

Karyopharm Announces 1-for-15 Reverse Stock Split

Karyopharm Therapeutics Inc. (KPTI) Q4 2024 Earnings Call Transcript

Feb 19, 2025, 11:05 AM EST - 1 year ago

Karyopharm Therapeutics Inc. (KPTI) Q4 2024 Earnings Call Transcript

Karyopharm Reports Fourth Quarter and Full Year 2024 Financial Results, Announces Update to Phase 3 XPORT-EC-042 Trial and Highlights Recent Company Progress

Feb 19, 2025, 7:30 AM EST - 1 year ago

Karyopharm Reports Fourth Quarter and Full Year 2024 Financial Results, Announces Update to Phase 3 XPORT-EC-042 Trial and Highlights Recent Company Progress

Antengene Announces XPOVIO® Approved for Public Health Insurance Coverage in Taiwan Market, Benefiting More Patients with R/R MM in the Region

Feb 13, 2025, 4:30 AM EST - 1 year ago

Antengene Announces XPOVIO® Approved for Public Health Insurance Coverage in Taiwan Market, Benefiting More Patients with R/R MM in the Region

Karyopharm to Report Fourth Quarter and Full Year 2024 Financial Results on February 19, 2025

Feb 12, 2025, 7:00 AM EST - 1 year ago

Karyopharm to Report Fourth Quarter and Full Year 2024 Financial Results on February 19, 2025

Karyopharm Announces Preliminary Unaudited 2024 Revenue and 2025 Objectives

Jan 13, 2025, 8:30 AM EST - 1 year ago

Karyopharm Announces Preliminary Unaudited 2024 Revenue and 2025 Objectives

Karyopharm Announces the Appointment of Lori Macomber as Chief Financial Officer

Jan 2, 2025, 7:00 AM EST - 1 year ago

Karyopharm Announces the Appointment of Lori Macomber as Chief Financial Officer

Karyopharm Announces the Appointment of Brendan Strong as Senior Vice President of Investor Relations and Corporate Communications

Dec 9, 2024, 8:00 AM EST - 1 year ago

Karyopharm Announces the Appointment of Brendan Strong as Senior Vice President of Investor Relations and Corporate Communications

Karyopharm Therapeutics Provides Endometrial Cancer Program Update

Dec 3, 2024, 7:00 AM EST - 1 year ago

Karyopharm Therapeutics Provides Endometrial Cancer Program Update

Karyopharm to Participate at the Piper Sandler 36th Annual Healthcare Conference

Nov 25, 2024, 7:00 AM EST - 1 year ago

Karyopharm to Participate at the Piper Sandler 36th Annual Healthcare Conference

Karyopharm Therapeutics Announces the Appointment of Chief Accounting Officer

Nov 20, 2024, 4:05 PM EST - 1 year ago

Karyopharm Therapeutics Announces the Appointment of Chief Accounting Officer

Karyopharm to Present Selinexor Data at the 66th American Society of Hematology Annual Meeting and Exposition

Nov 18, 2024, 7:00 AM EST - 1 year ago

Karyopharm to Present Selinexor Data at the 66th American Society of Hematology Annual Meeting and Exposition

Karyopharm Therapeutics Inc. (KPTI) Q3 2024 Earnings Call Transcript

Nov 5, 2024, 9:22 PM EST - 1 year ago

Karyopharm Therapeutics Inc. (KPTI) Q3 2024 Earnings Call Transcript

Antengene to Present Results from Two Late-Stage Studies of Selinexor Signaling Potential Clinical Breakthrough at ASH 2024

Nov 5, 2024, 7:30 PM EST - 1 year ago

Antengene to Present Results from Two Late-Stage Studies of Selinexor Signaling Potential Clinical Breakthrough at ASH 2024

Karyopharm Reports Third Quarter 2024 Financial Results and Highlights Recent Company Progress

Nov 5, 2024, 7:30 AM EST - 1 year ago

Karyopharm Reports Third Quarter 2024 Financial Results and Highlights Recent Company Progress

Karyopharm to Report Third Quarter 2024 Financial Results on November 5, 2024

Oct 31, 2024, 8:00 AM EDT - 1 year ago

Karyopharm to Report Third Quarter 2024 Financial Results on November 5, 2024

Karyopharm Announces Favorable Change in Co-Primary Endpoint for Pivotal Phase 3 SENTRY Trial in Myelofibrosis

Oct 31, 2024, 7:30 AM EDT - 1 year ago

Karyopharm Announces Favorable Change in Co-Primary Endpoint for Pivotal Phase 3 SENTRY Trial in Myelofibrosis

Karyopharm to Host Investor Event with Leading Myelofibrosis KOLs and Provide a Favorable Study Design Update on October 31, 2024

Oct 30, 2024, 4:30 PM EDT - 1 year ago

Karyopharm to Host Investor Event with Leading Myelofibrosis KOLs and Provide a Favorable Study Design Update on October 31, 2024

Antengene Announces XPOVIO® (selinexor) Approved for Its Third Indication in South Korea, Bringing Fresh Hope to Patients with MM in the Country

Oct 17, 2024, 10:35 PM EDT - 1 year ago

Antengene Announces XPOVIO® (selinexor) Approved for Its Third Indication in South Korea, Bringing Fresh Hope to Patients with MM in the Country

Antengene Announces XPOVIO® (selinexor) Approved for Commercialization in Thailand

Sep 23, 2024, 5:00 AM EDT - 1 year ago

Antengene Announces XPOVIO® (selinexor) Approved for Commercialization in Thailand

Karyopharm to Participate at Upcoming Investor Conferences

Sep 3, 2024, 7:00 AM EDT - 1 year ago

Karyopharm to Participate at Upcoming Investor Conferences

Karyopharm Reports Second Quarter 2024 Financial Results and Highlights Recent Company Progress

Aug 6, 2024, 7:30 AM EDT - 1 year ago

Karyopharm Reports Second Quarter 2024 Financial Results and Highlights Recent Company Progress

Antengene Announces XPOVIO® (selinexor) Approved for Commercialization in Malaysia

Aug 5, 2024, 8:00 PM EDT - 1 year ago

Antengene Announces XPOVIO® (selinexor) Approved for Commercialization in Malaysia

Karyopharm to Report Second Quarter 2024 Financial Results on August 6, 2024

Jul 31, 2024, 4:05 PM EDT - 1 year ago

Karyopharm to Report Second Quarter 2024 Financial Results on August 6, 2024

XPOVIO® (selinexor) Approved for New Indication in DLBCL in China, Bringing a New Treatment Option to Patients in the Country

Jul 5, 2024, 9:10 AM EDT - 1 year ago

XPOVIO® (selinexor) Approved for New Indication in DLBCL in China, Bringing a New Treatment Option to Patients in the Country

Antengene Announces XPOVIO® (selinexor) National Health Insurance Service Approval for Reimbursement in South Korea

Jun 26, 2024, 4:42 AM EDT - 1 year ago

Antengene Announces XPOVIO® (selinexor) National Health Insurance Service Approval for Reimbursement in South Korea

somalight
somalight Mar. 17 at 5:51 PM
$KPTI Is the outcome of this Phase 3 trial really that important? It doesn’t seem like many people are paying attention to whether it succeeds or fails, and I feel like the stock price reaction might be minimal.
1 · Reply
Selfmademan
Selfmademan Mar. 17 at 4:46 PM
$KPTI director, medical writing no longer taking applicants via linkedin... 🤔 hopefully hired and not just deleted. Yeah hopefully stellar results, perhaps tomorrow. Have 1k shares just in case.
0 · Reply
celebratelife
celebratelife Mar. 17 at 1:39 PM
$KPTI I looked at yesterday's options again at the end of the day, and there were a lot of bullish put and call trades. But it's always tell with certainty which side it's on and if it's a open or close. So everything I post here about options, take it as tentative and impression.
0 · Reply
laaarsas
laaarsas Mar. 17 at 1:08 PM
$KPTI I think results tomorrow! Wednesday is good resultsday. Or maybe if data is bad they release Friday?
0 · Reply
hbkstockislife
hbkstockislife Mar. 17 at 12:13 PM
$KPTI results won’t come or what
0 · Reply
celebratelife
celebratelife Mar. 16 at 5:04 PM
$KPTI Just now another big buy of March $17.50 calls at ask (Bullish) - counting price to go above 17.85 in next 4 days. Total: 134100 shares worth traded today and total open calls: 1054300 open interest. $47,000 bet the stock will go over 17.85 this week !!
1 · Reply
celebratelife
celebratelife Mar. 16 at 4:56 PM
$KPTI Solid May 2.50 put sale at bid (Bullish) 50100 shares worth.
0 · Reply
celebratelife
celebratelife Mar. 16 at 4:53 PM
$KPTI solid buy at ask: March $17.50 - 4 days to expiration - somebody thinks data will be released this week. 82700 shares worth.
0 · Reply
celebratelife
celebratelife Mar. 16 at 2:16 PM
$KPTI So far today: Multiple bullish option moves. A March bullish spread sale of put buy of call - based on analysis incl. impl. volt. -- and a bullish call and another bullish put sale April.
0 · Reply
laaarsas
laaarsas Mar. 16 at 12:15 PM
$KPTI data when?
1 · Reply
Gius_me
Gius_me Mar. 14 at 12:32 PM
$KPTI well, half month has passed. Let’s see next couple of weeks. Finally raise or die but in any case it will be clear
1 · Reply
elmono
elmono Mar. 14 at 12:16 AM
$KPTI if it hits: congrats….if it doesn’t: I get to buy sub 1 …..lets see
0 · Reply
celebratelife
celebratelife Mar. 13 at 8:24 PM
$KPTI More April 20 calls were bought at ask today.
0 · Reply
celebratelife
celebratelife Mar. 13 at 3:11 PM
$KPTI Most of today's option activity are call buys at ask (bullish). The CEO and Board suck no doubt but so are the manipulators.
1 · Reply
celebratelife
celebratelife Mar. 13 at 3:08 PM
$KPTI looks more like manipulation with high volume buys on the lows and drop on low volume. The biggest trade today was a buy at the bottom.
0 · Reply
Rabinovich
Rabinovich Mar. 13 at 2:39 PM
$KPTI The high-volume sell off continues. Unfortunately, the 'management' have no credibility left whatsoever and it can't be excluded that the results have been leaked.
1 · Reply
celebratelife
celebratelife Mar. 13 at 1:49 PM
$KPTI Reminder to the lousy, unethical, value destroyer CEO Richard Paulson: KPTI is 50 CENTS(down from double digits pre-RS) on his fucking watch.
0 · Reply
aletz
aletz Mar. 13 at 10:13 AM
$KPTI https://www.biostockinfo.com/biotech-catalyst-ai-scanner-march-wk3/ KPTI, the top pick from the AI Catalyst Scanner of March 3rd week, is worth checking out. For more catalyst-based biotech investment ideas, visit the link provided.
1 · Reply
celebratelife
celebratelife Mar. 12 at 7:25 PM
$KPTI Also August calls are bought at ask today including August $20 call that just traded at ask for 2.80 a contract.
2 · Reply
celebratelife
celebratelife Mar. 12 at 7:23 PM
$KPTI More April $20 calls bought at ask today. Very bullish. People are betting on the stock being above 21.90 on a market down day like this.
0 · Reply
celebratelife
celebratelife Mar. 12 at 5:26 PM
$KPTI 2500 contracts of May $20 calls opened today. Betting for 250,000 shares the stock will be over 21.85 by May opex.
0 · Reply
celebratelife
celebratelife Mar. 12 at 5:23 PM
$KPTI seems some day trader / swing trader has shorted, bashing to support that position. Says absolutely nothing about the data, esp. on a day when $XBI is down big.
0 · Reply